A Silver Milestone for Drug Development (English)
- New search for: Peters, R.
- New search for: Peters, R.
In:
BIOPHARM INTERNATIONAL
;
27
, 8
;
6
;
2014
-
ISSN:
- Article (Journal) / Print
-
Title:A Silver Milestone for Drug Development
-
Contributors:Peters, R. ( author )
-
Published in:BIOPHARM INTERNATIONAL ; 27, 8 ; 6
-
Publisher:
- New search for: Aster Publishing Corporation
-
Publication date:2014-01-01
-
Size:6 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 615
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 615 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 8
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 6
-
A Silver Milestone for Drug DevelopmentPeters, R. et al. | 2014
- 10
-
FDA seeks high quality applications and products to facilitate approvals and reduce safety and supply problemsWechsler, J. et al. | 2014
- 12
-
Annual study shows technical expertise is not enoughLanger, E. et al. | 2014
- 16
-
Single-use products offer options and choices for biopharma mixingMartin, J. et al. | 2014
- 20
-
SINGLE-DOMAIN ANTIBODIES Single-Domain Antibodies for Brain Targeting Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant productionLalatsa, A. / Leite, D.M. et al. | 2014
- 28
-
RAW MATERIALS TESTING Ensuring the Safety, Quality, and Identity of Biopharmaceutical Raw Materials Going beyond requirements is essential for the quality and safety of raw materialsChallener, C.A. et al. | 2014
- 30
-
PEER-REVIEWED Environmental Responsibility in Chinese Biopharmaceutical Companies This paper presents a new perspective that calls for an integration of corporate environmental responsibiiity into the business strategy of biopharmaceutical companiesWei, L. / Ruixiang, Y. et al. | 2014
- 36
-
PERSONALIZED MEDICINE Marrying Big Data with Personalized Medicine Data analytic strategies can help companies capitalize on personalized medicineSuckman, J.E. / Kuchenreuther, M. et al. | 2014
- 40
-
Defining best biopharmaceutical practices is necessary to ensure the safety of the supply chainChalk, S. et al. | 2014
- 46
-
Part II of this three-part series presents a roadmap to human error preventionMcAuley, G. et al. | 2014